Cargando…

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer

SIMPLE SUMMARY: Mitotane is the only drug approved for treatment of adrenocortical cancer. Although mitotane is a derivative of the pesticide dichlorodiphenyltrichloroethane (DDT), limited data are available on its toxicity. Herein, we reported on the type and frequency of mitotane adverse events an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basile, Vittoria, Puglisi, Soraya, Calabrese, Anna, Pia, Anna, Perotti, Paola, Berruti, Alfredo, Reimondo, Giuseppe, Terzolo, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565701/ https://www.ncbi.nlm.nih.gov/pubmed/32937772 http://dx.doi.org/10.3390/cancers12092615

Ejemplares similares

Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
por: Allegra, Sarah, et al.
Publicado: (2022)

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2019)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies
por: Lo Iacono, Marco, et al.
Publicado: (2021)

Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma
por: Allegra, Sarah, et al.
Publicado: (2021)

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
por: Poirier, Jonathan, et al.
Publicado: (2020)

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
por: Germano, Antonina, et al.
Publicado: (2020)

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
por: Puglisi, Soraya, et al.
Publicado: (2020)

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
por: Terzolo, Massimo, et al.
Publicado: (2021)

CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells
por: Germano, Antonina, et al.
Publicado: (2018)

THU617 Prolonged Exposure To Target Mitotane Concentrations Is Associated With Better Recurrence-free Survival In Patients With Adrenocortical Carcinoma On Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2023)

OR12-1 Activity of Abiraterone Acetate in the management of Cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial.
por: Abate, Andrea, et al.
Publicado: (2022)

Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study
por: Terzolo, Massimo, et al.
Publicado: (2023)

THU616 Analysis Of Germline Mutations In Patients With Sporadic Adrenocortical Carcinoma
por: Terzolo, Massimo, et al.
Publicado: (2023)

Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane
por: Cantini, Giulia, et al.
Publicado: (2023)

SUN-350 Sterol-O-Acyl Transferase 1 Protein Expression Alone Is Not Sufficient to Predict Response to Mitotane Treatment in Adrenocortical Carcinoma
por: Weigand, Isabel, et al.
Publicado: (2019)

Mitotane in adrenocortical carcinoma.
por: Vassilopoulou-Sellin, R., et al.
Publicado: (1994)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
por: Gagnon, Nadia, et al.
Publicado: (2022)

SAT-365 Prevalence and Clinical Features of Adrenal Incidentalomas: A Prospective Study in an Unselected Population
por: Castellano, Elena, et al.
Publicado: (2019)

Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study
por: Altieri, Barbara, et al.
Publicado: (2020)

Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study
por: Kimpel, Otilia, et al.
Publicado: (2021)

Is Follow-up of Adrenal Incidentalomas Always Mandatory?
por: Reimondo, Giuseppe, et al.
Publicado: (2020)

CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma
por: Ronchi, Cristina L., et al.
Publicado: (2014)

Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis
por: Tang, Yongquan, et al.
Publicado: (2018)

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019)

Preoperative treatment with metyrapone in patients with Cushing’s syndrome due to adrenal adenoma: a pilot prospective study
por: Puglisi, Soraya, et al.
Publicado: (2018)

Limited Role of Hair Cortisol and Cortisone Measurement for Detecting Cortisol Autonomy in Patients With Adrenal Incidentalomas
por: Puglisi, Soraya, et al.
Publicado: (2022)

High‐Dose Mitotane‐Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma
por: Pape, Elise, et al.
Publicado: (2017)

Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer
por: Head, Lia, et al.
Publicado: (2019)

Generation and characterization of a mitotane-resistant adrenocortical cell line
por: Seidel, Eric, et al.
Publicado: (2020)

Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma
por: Warde, Kate M, et al.
Publicado: (2022)

Adrenal Hyperplasia as Possible Predictor of Mortality in Patients Admitted for Suspected SARS-Cov-2 Infection: A Prospective Study
por: Reimondo, Giuseppe, et al.
Publicado: (2021)

Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study
por: Delbarba, Andrea, et al.
Publicado: (2023)

Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor
por: Oddie, Philip D, et al.
Publicado: (2018)

Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane
por: Alam, Walid, et al.
Publicado: (2021)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Investigating the Role of Cholesterol and Lipid Trafficking in Mitotane Resistance in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2021)

Case Report: Adjuvant Therapy with a High Dose of Mitotane for Adrenocortical Carcinoma in a 4-year-old Boy
por: Goto, Takako, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_aao6kkbhb4hv6uaenu71kpsbgl